Linking microstructural integrity and motor cortex excitability in multiple sclerosis

Angela Radetz; Kalina Mladenova; Dumitru Ciolac; Gabriel Gonzalez-Escamilla; Vinzenz Fleischer; Erik Ellwardt; Julia Krämer; Stefan Bittner; Sven G. Meuth; Muthuraman Muthuraman; Sergiu Groppa

doi:10.1101/2020.10.15.20213090

Abstract

Motor skills are frequently impaired in multiple sclerosis (MS) patients following grey (GM) and white matter (WM) damage with cortical excitability abnormalities. We performed advanced diffusion imaging for neurite orientation dispersion and density modeling and diffusion tensor imaging within the motor system of 50 MS patients and 49 age-matched healthy controls. To assess excitability, we determined resting motor thresholds using non-invasive transcranial magnetic stimulation. A hierarchical regression model revealed that lower neurite density index (NDI), suggestive for axonal loss in the GM, predicted higher motor thresholds, i.e. reduced excitability in MS patients. Furthermore, lower NDI was indicative of decreased cognitive-motor performance. Interconnected motor WM tracts of patients were characterized by overlapping clusters of lowered fractional anisotropy and NDI, with NDI exclusively capturing a higher amount of abnormally appearing voxels. Our work outlines the potential of microstructure imaging using advanced biophysical models to forecast neurodegeneration and excitability alterations in neuroinflammation.

Competing Interest Statement

S. G. Meuth has received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kroener Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. J. Kraemer received honoraria for lecturing from Biogen, Novartis, Merck Serono, Sanofi-Genzyme, Roche, Mylan and Teva, and financial research support from Sanofi Genzyme. S. Bittner has received honoraria and compensation for travel from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme and Roche.

Funding Statement

This study was supported by the German Research Council (DFG, CRC TR-128 to S.B., S.G.M., S.G.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the local Ethics Committee of the State Medical Association of Rhineland-Palatinate.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes